Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.
Kobayashi K, Matsumoto H, Sakano S, Yamamoto M, Tsuchida M, Tei Y, Nagao K, Oba K, Kitahara S, Yano S, Yoshihiro S, Yamamoto Y, Ohmi C, Komatsu H, Misumi T, Akao J, Shiraishi K. Kobayashi K, et al. Among authors: yamamoto y, yamamoto m. Clin Genitourin Cancer. 2024 Dec;22(6):102212. doi: 10.1016/j.clgc.2024.102212. Epub 2024 Aug 23. Clin Genitourin Cancer. 2024. PMID: 39270620
Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines.
Sakano S, Matsuyama H, Takai K, Yoshihiro S, Kamiryo Y, Shirataki S, Kaneda Y, Hashimoto O, Joko K, Suga A, Yamamoto M, Hayashida S, Baba Y, Aoki A; Yamaguchi Uro-Oncology Group. Sakano S, et al. Among authors: yamamoto m. BJU Int. 2011 May;107(10):1598-604. doi: 10.1111/j.1464-410X.2010.09850.x. Epub 2010 Nov 18. BJU Int. 2011. PMID: 21087393
Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Shimabukuro T, Sakano S, Matsuda K, Kamiryo Y, Yamamoto N, Kaneda Y, Nasu T, Baba Y, Suga A, Yamamoto M, Aoki A, Takai K, Yoshihiro S, Konishi M, Imoto K, Matsuyama H. Shimabukuro T, et al. Among authors: yamamoto n, yamamoto m. Int J Clin Oncol. 2013 Feb;18(1):62-7. doi: 10.1007/s10147-011-0344-x. Epub 2011 Nov 3. Int J Clin Oncol. 2013. PMID: 22068464
Risk group stratification based on preoperative factors to predict survival after nephroureterectomy in patients with upper urinary tract urothelial carcinoma.
Sakano S, Matsuyama H, Kamiryo Y, Hayashida S, Yamamoto N, Kaneda Y, Nasu T, Hashimoto O, Joko K, Baba Y, Shimabukuro T, Suga A, Yamamoto M, Aoki A, Takai K, Yoshihiro S, Matsumura M; Yamaguchi Uro-Oncology Group. Sakano S, et al. Among authors: yamamoto n, yamamoto m. Ann Surg Oncol. 2013 Dec;20(13):4389-96. doi: 10.1245/s10434-013-3259-0. Epub 2013 Sep 18. Ann Surg Oncol. 2013. PMID: 24046115
Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma.
Sakano S, Matsuyama H, Kamiryo Y, Hayashida S, Yamamoto N, Kaneda Y, Nasu T, Baba Y, Shimabukuro T, Suga A, Yamamoto M, Aoki A, Takai K, Yoshihiro S, Oba K; Yamaguchi Uro-Oncology Group. Sakano S, et al. Among authors: yamamoto n, yamamoto m. Int J Clin Oncol. 2015 Apr;20(2):362-8. doi: 10.1007/s10147-014-0721-3. Epub 2014 Jun 27. Int J Clin Oncol. 2015. PMID: 24964974
Use of preoperative performance status and hemoglobin concentration to predict overall survival for patients aged ≥ 75 years after radical cystectomy for treatment of bladder cancer.
Hara T, Matsuyama H, Kamiryo Y, Hayashida S, Yamamoto N, Nasu T, Joko K, Baba Y, Suga A, Yamamoto M, Aoki A, Takai K, Yoshihiro S, Konishi M, Sakano S, Imoto K, Tei Y, Yamaguchi S, Yano S; Yamaguchi Uro-Onocology Group. Hara T, et al. Among authors: yamamoto n, yamamoto m. Int J Clin Oncol. 2016 Feb;21(1):139-47. doi: 10.1007/s10147-015-0857-9. Epub 2015 Jun 16. Int J Clin Oncol. 2016. PMID: 26077140
Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
Nagao K, Matsuyama H, Matsumoto H, Nasu T, Yamamoto M, Kamiryo Y, Baba Y, Suga A, Tei Y, Yoshihiro S, Aoki A, Shimabukuro T, Joko K, Sakano S, Takai K, Yamaguchi S, Akao J, Kitahara S; Yamaguchi Uro-Oncology Group. Nagao K, et al. Among authors: yamamoto m. Int J Clin Oncol. 2018 Aug;23(4):757-764. doi: 10.1007/s10147-018-1272-9. Epub 2018 Mar 27. Int J Clin Oncol. 2018. PMID: 29589154 Free PMC article.
Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.
Yamamoto Y, Yatsuda J, Shimokawa M, Fuji N, Aoki A, Sakano S, Yamamoto M, Suga A, Tei Y, Yoshihiro S, Kitahara S, Nagao K, Takai K, Kamiryo Y, Akao J, Yamaguchi S, Oba K, Shimabukuro T, Matsumoto H, Kamba T, Matsuyama H. Yamamoto Y, et al. Among authors: yamamoto m. Int J Clin Oncol. 2021 Jan;26(1):169-177. doi: 10.1007/s10147-020-01784-w. Epub 2020 Sep 18. Int J Clin Oncol. 2021. PMID: 32948925
Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors.
Kobayashi K, Sakano S, Matsumoto H, Yamamoto M, Tsuchida M, Tei Y, Nagao K, Oba K, Kitahara S, Yano S, Yoshihiro S, Yamamoto Y, Ohmi C, Komatsu H, Misumi T, Akao J, Shiraishi K. Kobayashi K, et al. Among authors: yamamoto y, yamamoto m. Jpn J Clin Oncol. 2024 Oct 7:hyae137. doi: 10.1093/jjco/hyae137. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39373462
13,311 results
You have reached the last available page of results. Please see the User Guide for more information.